Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Neoplasm Metastasis 2Endometrial Neoplasms 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1High Grade Serous Carcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 47enzalutamide 46apalutamide 36Specimen Handling 30Androgen Antagonists 30Abiraterone Acetate 29Radiosurgery 26Prednisone 25darolutamide 24Docetaxel 23Pluvicto 21abiraterone 19Radiotherapy 19Biopsy 17Leuprolide 15Surveys and Questionnaires 11Radiation 112-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 11relugolix 10gallium 68 PSMA-11 10acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 10Standard of Care 10Nivolumab 10cabazitaxel 9Triptorelin Pamoate 9bicalutamide 8Carboplatin 8pembrolizumab 7olaparib 7niraparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × ceralasertib × 90 days × Clear all
NCT03787680 2026-03-23

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

University of Michigan Rogel Cancer Center

Phase 2 Active not recruiting
49 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡